Objective: Estrogen is a well-known oncogenic driver in endometrial (ECs) and breast cancers (BCs). Programmed cell death protein 1 (PD-1) and its ligands PD-1 Ligand 1 (PD-L1) and PD-L2 have been shown to mediate immune evasion of the tumor cells. The purpose of the present study was to assess the effects of estrogen on PD-L1 and PD-L2 expression in EC and BC cell lines. 
E ndometrial cancer (EC) and breast cancer (BC) are two common malignancies in women worldwide. 1 Type 1 EC includes endometrial adenocarcinoma that represents 80% to 90% EC arising from atypical endometrial hyperplasia with unopposed estrogen exposure. 2, 3 Likewise, increased lifetime exposure to estrogen as inferred by early menarche, late menopause, or obesity is associated with an increased BC risk. 4, 5 The majority of EC and BC are estrogen-dependent adenocarcinomas with estrogen receptor > (ER>) expression. Estrogen-stimulated cellular proliferation remains the conceptual underpinning of ER>-dependent mechanism in EC and BC development and progression. 6 Recently, the B7-CD28 family of immune checkpoint proteins has been demonstrated to play key roles in regulating T-cell activation and immunological tolerance. 7 T cells, natural killer cells, monocytes, and B cells have been shown to express programmed cell death protein 1 (PD-1), a member of the B7-CD28 family. 8, 9 The ligands for PD-1 (PD-Ls) are PD-L1 (also known as B7-H1) and PD-L2 (also named B7-DC), both of which can be found not only on immune cells, but also in cancer cells including lung cancer, ovarian cancer, colon cancer, and melanoma.
10Y12 Tumor-associated PD-L1 can be induced by various factors, including interferon (IFN) family, tumor necrosis factor >, vascular endothelial growth factor, and cytokines such as interleukin-4 (IL-4) and IL-10.
10,13Y15
In the tumor microenvironment, PD-Ls act through PD-1 to inhibit T-cell proliferation, reduce T-cell activation, and induce T-cell apoptosis. 9, 16, 17 Substantial preclinical and clinical evidences have proved that PD-1/PD-Ls play a major role in immune suppression within the tumor microenvironment and anti-PD-1/PD-L1 antibodies are effective in the treatment of multiple cancers. 10 ,18Y21 Therefore, the US Food and Drug Administration has approved 2 anti-PD-1 monoclonal antibodies (nivolumab and pembrolizumab) for treatment of unresectable or metastatic melanoma, nonYsmall cell lung carcinoma, and metastatic renal cell carcinoma, based on clinical efficacy and safety data. 20Y23 Aside from anti-PD-1 antibodies, anti-PD-L1 atezolizumab has been shown to be efficacious in bladder cancer and nonYsmall cell lung carcinoma 24Y26 and has recently been approved for treatment of locally advanced or metastatic urothelial carcinoma.
Previously, we have studied PD-1/PD-Ls in human lung cancer, 27 human cervical intraepithelial neoplasia, 28 and mouse prostate cancer. 29 Particularly, we have found that 61.3% of ECs were positive for PD-1 expression, and PD-L1/2 expression was increased in poorly differentiated ECs. 30 Therefore, we became interested in investigating the factors that could regulate the expression of PD-Ls in cancer cells. Because estrogen is a well-known oncogenic driver in EC and BC, and it is not known whether 17A-estradiol (E2) can regulate PD-Ls expression in cancer cells, we conducted this study with the aim to assess the effects of E2 on PD-Ls expression in EC and BC cells.
MATERIALS AND METHODS

Cell Culture
Human EC cell line Ishikawa (ER>-positive), human BC cell lines MCF-7 (ER>-positive) and MDA-MB-231 (ER>-negative), and Jurkat cells (immortalized from acute T-cell leukemia and often used as T lymphocytes) were purchased from the American Type Culture Collection (Manassas, Va) and were free of mycoplasma contamination. Human primary T cells were isolated from donated blood and obtained from State/ National Key Laboratory of Biotherapy, Sichuan University. The cells were cultured in Dulbecco Modified Eagles Medium (DMEM; Fisher Scientific, Waltham, Mass) supplemented with 10% fetal bovine serum (FBS; Fisher Scientific) and 100 U/mL penicillin/streptomycin in a humidified incubator with 5% CO 2 at 37-C. Jurkat and primary T cells were cultured in RPMI-1640 medium (Fisher Scientific) supplemented with 10% FBS and 100 U/mL penicillin/streptomycin in a humidified incubator with 5% CO 2 at 37-C. 
Western Blot
After the indicated time of treatment, proteins were extracted from the cells in radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM sodium fluoride, 0.5% Igepal CA-630 [NP-40], 10 mM sodium phosphate, 150 mM sodium chloride, 25 mM Tris pH 8.0, 1 mM phenylmethylsulfonyl fluoride, 2 mM ethylenediaminetetraaceticacid [EDTA], 1.2 mM sodium vanadate) supplemented with protease inhibitor cocktail (SigmaAldrich). Equal amount of proteins was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane. The membranes were blocked with 5% nonfat dry milk in Tris buffered saline-Tween 20 buffer (25 mM TrisYHCl, 125 mM NaCl, 0.1% Tween-20) for 1 hour and probed with the indicated primary antibodies overnight and then IRDye 800CW-or IRDye 680RD-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, Neb) for 1 hour. The results were visualized using an Odyssey Infrared Imager (LI-COR Biosciences). For loading control, the membranes were stripped and probed for unphosphorylated proteins and/or GAPDH. Quantification of the Western blot signals was performed using the image analysis software of the Odyssey Infrared Imager system. The integrated density values of signals of targeted genes were normalized by those of GAPDH. The ratio indicates the relative level of target protein.
Functional Analysis of T Cells After Cocultured With Ishikawa or MCF-7 Cells
Jurkat cells and human primary T cells were used for functional analysis. Previous studies have found that Jurkat cells express low basal levels of PD-1 mRNA and protein, which is responsive to anti-PD-L1 antibody. 31, 32 We also confirmed that Jurkat cells express PD-1 mRNA and protein before using this cell line (data not shown). 1 Â 10 6 of T cells (Jurkat or primary T cells) and 1 Â 10 6 of cancer cells (Ishikawa or MCF-7 cells) were cocultured in 6-cm dishes. In addition, antiYhuman PD-L1 (1 Kg/mL) or isotype mouse IgG (1 Kg/mL) were added to cancer cells. After incubation for 2 hours, the antibody-treated cancer cells were added to dishes containing T cells. After 16 hours 
Statistical Analysis
Statistical analysis was performed using SPSS (v17.0, SPSS Inc, Chicago, Ill). Data are presented as mean T standard error (SE). Quantitative data were analyzed using Student t test (2-tailed). Statistical significance was reached with a P value less than 0.05.
RESULTS
17A-Estradiol Does Not Regulate PD-L1 and PD-L2 mRNA Expression
To assess E2's effects on PD-L1 and PD-L2 expression, we tested 2 cancer cell lines (Ishikawa and MCF-7) with ER> protein expression and 1 cancer cell line (MDA-MB-231) without ER> protein expression as negative control. We first confirmed that Ishikawa and MCF-7 cell lines were ER>-positive and MDA-MB-231 cell line was ER>-negative (Fig. 1A) . We found that E2 at doses from 1 to 10 nM did not induce significant changes in PD-L1 and PD-L2 mRNA levels (P 9 0.05, Fig. 1B ). 17A-Estradiol at a dose of 10 nM did not induce significant changes in PD-L1 and PD-L2 mRNA levels during a time-course of 2 to 24 hours (P 9 0.05, Fig. 1C ).
17A-Estradiol Increases PD-L1 Protein Expression in ER>-Positive Cells via Activation of PI3K/Akt Pathway
We found that E2 at doses of 1 to 10 nM significantly increased PD-L1, but not PD-L2, protein expression in Ishikawa ( Fig. 2A) and MCF-7 (Fig. 2B) cell lines, but not in MDA-MB-231 cell line (Fig. 2C) . 17A-Estradiol at a dose of 10 nM increased PD-L1, but not PD-L2, protein expression in a time-dependent manner in Ishikawa (Fig. 3A) and MCF-7 (Fig. 3B) cell lines, but not in MDA-MB-231 cell line (Fig. 3C) . Akt activation, based on phosphorylated Akt (p-Akt) levels, seemed to coincide with or precede the increased PD-L1 protein levels in Ishikawa (Fig. 3A) and MCF-7 ( Fig. 3B) cell lines, but not in MDA-MB-231 cell line (Fig. 3C ). Of note, total Akt (t-Akt) levels were also increased by E2 treatment in Ishikawa cell line (Fig. 3A) .
To determine if E2-activated PI3K/Akt signaling pathway regulated PD-L1 protein expression, we treated Ishikawa and MCF-7 cells with a pharmacologic inhibitor of PI3K (LY294002) and a pan-Akt inhibitor AZD5363. We found that LY294002 completely blocked Akt activation and decreased E2-induced PD-L1 protein expression in Ishikawa and MCF-7 cells (Fig. 4A, B) . Consistently, AZD5363 maintained p-Akt levels but decreased E2-induced PD-L1 protein expression in Ishikawa and MCF-7 cells (Fig. 4C, D) .
17A-Estradiol Increases PD-L1 mRNA Stability but not Protein Stability Through Activation of Akt
To explore the mechanisms of how E2 increased PD-L1 protein expression, we checked PD-L1 mRNA levels in Ishikawa and MCF-7 cells after blocking transcription by ActD treatment. We found that PD-L1 mRNA levels quickly decreased in the presence of ActD, however, with addition of 10 nM E2, the decrease of PD-L1 mRNA levels were significantly slowed down. When 2 KM AZD5363 was added to inhibit Akt function, E2 was unable to stabilize PD-L1 mRNA levels (Fig. 5A) . In contrast, when protein translation was blocked by CHX treatment, E2 did not change the rate of decrease at PD-L1 protein levels in Ishikawa and MCF-7 cells (Fig. 5B) . 
17A-Estradiol Inhibits T-cell Function in Coculture of Ishikawa or MCF-7 and T Cells
To determine if E2-induced PD-L1 protein expression was immunologically relevant, Jurkat or primary T cells were cocultured with cancer cells (Fig. 6A, B, F, G) . We found that E2 significantly increased IL-2 mRNA levels in Jurkat cells (Fig. 6C) , but not in primary T cells (Fig. 6H) , in the absence of coculturing with any cancer cells. However, in coculture of Ishikawa or MCF-7 and Jurkat or primary T cells, E2 significantly decreased mRNA levels of IFN-F and IL-2 in Jurkat and primary T cells (Fig. 6D, E, I, J) . Anti-PD-L1 antibody, but not IgG, reversed E2-induced downregulation of IFN-F and IL-2 in Jurkat and primary T cells (Fig. 6D, E, I , J). Of note, E2 did not affect IFN-F or Bim mRNA expression in the absence of coculture with cancer cells (Fig. 6C, H) . In contrast, E2 slightly increased Bim mRNA levels in Jurkat cells cocultured with Ishikawa or MCF-7 cells, and the increase reached statistical significance in only MCF-7 cells (Fig. 6D, E) . In addition, in coculture of Ishikawa or MCF-7 and primary T cells, E2 significantly increased Bim mRNA level in primary T cells. Yet, E2-induced Bim upregulation was abolished by anti-PD-L1 antibody, but not by IgG (Fig. 6E, I , J).
DISCUSSION
Cancer development and progression require evasion of immune attack through upregulation of immune inhibitory factors in cancer cells. 33 One of these inhibitory factors is PD-L1, which binds to PD-1 expressed on T cells, B cells, natural killer cells, and dendritic cells to suppress anticancer immunity. On the other hand, it is not a bad thing to have high levels FIGURE 5. 17A-Estradiol's effects on PD-L1 mRNA and protein stability. A, Cancer cells were exposed to 5 Kg/mL ActD, with or without 10 nM E2, and 2 KM AZD5363 for the indicated time points; PD-L1 mRNA levels were assessed by qRT-PCR; data represent mean T SE, *P G 0.01. B, Cancer cells were exposed to 50 Kg/mL CHX, with or without 10 nM E2, for the indicated time points; PD-L1 protein levels were assessed by Western blot analysis. The integrated density values of signals of targeted genes were normalized by those of GAPDH based on Western blot analysis. Relative protein levels were calculated by the ratio of PD-L1/GAPDH. Data are presented as mean T SE of 3 independent experiments.
of PD-L1 expressed in cancer cells because there are a number of studies indicating that PD-L1 expression in cancer may be a good prognosis factor for cancer patients in certain cases. For example, PD-L1 mRNA expression is identified in nearly 60% of breast tumors, and it is associated with increased number of tumor-infiltrated lymphocytes and improved recurrence-free survival. 34 PD-L1 expression is often associated with high number of tumor-infiltrated lymphocytes, thus providing a good target for anti-PD-1/PD-L1 blockade therapy. 35 In the present study, we found that E2 remarkably increased PD-L1 protein expression in dose-and time-dependent manners, suggesting that E2 can regulate anticancer immunity. Indeed, we found that E2 inhibited T-cell functions in coculture of Jurkat or primary T cells with cancer cells. It is well known that E2 stimulates cancer cell proliferation to drive cancer development and progression. 6 The present study adds a new role of E2 in suppressing anticancer immunity through increasing PD-L1 protein expression in EC and BC cells.
Interestingly, PD-L2 expression was not affected by E2, suggesting that the regulatory mechanisms for PD-L1 and PD-L2 expression are different. 17A-Estradiol acts through ER>, which was why E2-induced PD-L1 protein expression was found in ER>-positive Ishikawa and MCF-7 cells, but not in ER>-negative MDA-MB-231 cells. In contrast to induction of PD-L1 protein expression, E2 did not affect PD-L1 mRNA expression (Fig. 1B, C) . At 10 nM dose, E2 only slightly increased PD-L1 mRNA levels (Fig. 1B) , which was not significant statistically. Because E2 did not affect PD-L1 mRNA transcription, we focused on nongenomic actions of E2. Previous studies have demonstrated that E2 rapidly activates PI3K/Akt signaling pathway in Ishikawa and MCF-7 cells, 36, 37 which is dependent on membrane ER> binding to p85> regulatory subunit of PI3K. 38, 39 It has been well established that E2 can activate PI3K/Akt signaling pathway, 40, 41 which is consistent with our findings in the present study. We showed that activation of PI3K/Akt is essential for E2-induced PD-L1 protein expression because PI3K and Akt inhibitors can completely block E2's effects. Of note, we observed that Akt was maintained in a hyperphosphorylated but catalytically inactive form in Ishikawa and MCF-7 cells after AZD5363 treatment. This phenomenon was also reported by other investigators. 42, 43 One possible mechanism is that Akt inhibitor sensitizes the Akt plekstrin homology domain binding to phosphatidylinositol (3,4,5)-trisphosphate, which facilitates membrane localization of Akt and induces conformational change of Akt, making it more susceptible to kinase phosphorylation or less susceptible to phosphatase dephosphorylation. 44 A previous study has shown that human immunodeficiency virus can activate PI3K/Akt to upregulate PD-L1 expression. 45 Furthermore, it has been shown that PI3K/Akt regulates PD-L1 expression at posttranscriptional levels. 46 We found that E2 increased PD-L1 mRNA stability, but not protein stability. This is consistent with a previous report that PI3K/Akt can inhibit mRNA degradation. 47 T cells express IFN-F to attack target cells and IL-2 to stimulate proliferation and survival of T cells. 9, 14 We found that E2 treatment decreased expression of IFN-F and IL-2 in Jurkat or primary T cells cocultured with cancer cells, suggesting that E2-induced PD-L1 protein in cancer cells inhibits T-cell functions. On the other hand, E2 increased expression of Bim, an initiator of T-cell apoptosis, 48 in Jurkat or primary T cells cocultured with cancer cells, indicating that E2-induced PD-L1 protein may lead to T-cell apoptosis, thus contributing to immunosuppression. It has been demonstrated that Bim is a downstream molecule of PD-1 signaling pathway in T cells. 49, 50 Thus, it is worth pointing out that E2 increases Bim expression through induction of PD-L1 because treatment with anti-PD-L1 antibody can abolish E2-induced Bim upregulation in Jurkat and primary T cells (Fig. 6E, I , J).
In conclusion, the present study provides the first evidence that E2 activates PI3K/Akt pathway to increase PD-L1 protein expression in ER>-positive EC and BC cells, which is through a posttranscriptional mechanism to stabilize PD-L1
mRNA. Our results demonstrate a new role of estrogen in regulation of anticancer immunity, implying PD-L1 as a potential therapeutic target and/or an outcome parameter in antiestrogen treatment of ECs and BCs.
